Axonics Modulation Technologies (AXNX) Surpasses Q2 Earnings and Revenue Estimates
- Axonics Modulation Technologies (AXNX) came out with quarterly earnings of $0.13 per share, beating the Zacks Consensus Estimate of $0.08 per share. This compares to loss of $0.15 per share a year ago.
- 08/01/2024
|
Axonics, Inc. (NASDAQ:AXNX) Shares Sold by Amalgamated Bank
- Amalgamated Bank cut its holdings in shares of Axonics, Inc. (NASDAQ:AXNX – Free Report) by 6.6% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 7,052 shares of the company’s stock after selling 499 shares during the period. Amalgamated Bank’s holdings in Axonics were worth $439,000 at the end of the most recent quarter. Several other institutional investors and hedge funds have also added to or reduced their stakes in AXNX. Headlands Technologies LLC acquired a new stake in shares of Axonics during the fourth quarter valued at approximately $53,000. RiverPark Advisors LLC acquired a new stake in shares of Axonics during the third quarter valued at approximately $58,000. C M Bidwell & Associates Ltd. raised its holdings in shares of Axonics by 108.2% during the third quarter. C M Bidwell & Associates Ltd. now owns 1,270 shares of the company’s stock valued at $71,000 after acquiring an additional 660 shares during the period. Sentry Investment Management LLC acquired a new stake in shares of Axonics during the fourth quarter valued at approximately $125,000. Finally, Covestor Ltd raised its holdings in shares of Axonics by 40.8% during the third quarter. Covestor Ltd now owns 3,143 shares of the company’s stock valued at $176,000 after acquiring an additional 911 shares during the period. 99.48% of the stock is owned by institutional investors and hedge funds. Axonics Stock Down 0.2 % AXNX stock opened at $67.55 on Monday. The company has a market capitalization of $3.45 billion, a price-to-earnings ratio of -211.09 and a beta of 0.60. Axonics, Inc. has a 12 month low of $47.59 and a 12 month high of $69.68. The firm has a 50 day moving average of $67.72 and a two-hundred day moving average of $64.46. Axonics (NASDAQ:AXNX – Get Free Report) last posted its earnings results on Tuesday, April 30th. The company reported ($0.38) EPS for the quarter, missing the consensus estimate of ($0.06) by ($0.32). The business had revenue of $91.41 million during the quarter, compared to the consensus estimate of $89.79 million. Axonics had a negative return on equity of 2.58% and a negative net margin of 4.12%. The business’s revenue was up 29.4% on a year-over-year basis. During the same period in the prior year, the firm earned ($0.19) earnings per share. On average, research analysts expect that Axonics, Inc. will post 0.13 EPS for the current fiscal year. Wall Street Analysts Forecast Growth AXNX has been the topic of a number of recent analyst reports. Needham & Company LLC restated a “hold” rating on shares of Axonics in a report on Monday, May 6th. Royal Bank of Canada reiterated a “sector perform” rating and issued a $71.00 price objective on shares of Axonics in a research note on Thursday, February 29th. Eight analysts have rated the stock with a hold rating and five have issued a buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $70.73. Read Our Latest Analysis on Axonics Axonics Profile (Free Report) Axonics, Inc, a medical technology company, engages in the development and commercialization of novel products for the treatment of bladder and bowel dysfunction. Its sacral neuromodulation (SNM) systems are used to treat patients with overactive bladder (OAB), including urinary urge incontinence and urinary urgency frequency, as well as fecal incontinence (FI) and non-obstructive urinary retention (UR); and rechargeable (R20) and recharge-free (F15) implantable SNM systems that delivers mild electrical pulses to the targeted sacral nerve to restore normal communication to and from the brain to reduce the symptoms of OAB, UR, and FI.
- 05/20/2024
|
Axonics Receives Regulatory Approval for Recharge-Free SNM System in Australia
- IRVINE, Calif.--(BUSINESS WIRE)--Axonics, Inc. (Nasdaq: AXNX) today announced that it has received regulatory approval from the Therapeutic Goods Administration (TGA) for marketing the Axonics F15™ recharge-free sacral neuromodulation (SNM) system in Australia to treat adults with overactive bladder. “Approval of the Axonics recharge-free system is welcome news for Australians with bladder and bowel dysfunction,” said Dr. Ailsa Wilson Edwards, a urologist at Calvary North Adelaide Hospital. “I.
- 05/16/2024
|
Axonics Reports First Quarter 2024 Financial Results
- IRVINE, Calif.--(BUSINESS WIRE)--Axonics, Inc. (Nasdaq: AXNX), a medical technology company that develops and commercializes innovative and minimally invasive products to treat bladder and bowel dysfunction, today reported financial results for the three months ended March 31, 2024. “Our commercial team continued to execute at a high level in the first quarter, generating revenue growth of 29% year over year across our portfolio of incontinence products,” said Raymond W. Cohen, chief executive.
- 04/30/2024
|
Boston Scientific Announces Results for First Quarter 2024
- MARLBOROUGH, Mass. , April 24, 2024 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) generated net sales of $3.856 billion during the first quarter of 2024, growing 13.8 percent on a reported basis, 15.0 percent on an operational1 basis and 13.1 percent on an organic2 basis, all compared to the prior year period.
- 04/24/2024
|
FTC seeks more information on Boston Scientific's $3.7 bln Axonics deal
- Boston Scientific said on Thursday the U.S. Federal Trade Commission (FTC) has requested additional information from the medical device maker related to its $3.7 billion deal to buy Axonics.
- 04/04/2024
|
All You Need to Know About Axonics (AXNX) Rating Upgrade to Buy
- Axonics (AXNX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
- 03/29/2024
|
Axonics Stockholders Approve Merger Agreement with Boston Scientific
- IRVINE, Calif.--(BUSINESS WIRE)--Axonics, Inc. (Nasdaq: AXNX) announced that its stockholders have voted today to adopt Axonics' merger agreement with Boston Scientific Corporation (NYSE: BSX). According to preliminary voting results from the special meeting of stockholders held earlier today, a majority of the shares of Axonics' common stock outstanding and entitled to vote at the special meeting voted in favor of adopting the merger agreement. Final voting results, as tabulated by an independ.
- 03/22/2024
|
Axonics Provides Update on Inter Partes Review Proceedings
- IRVINE, Calif.--(BUSINESS WIRE)--Axonics, Inc. (Nasdaq: AXNX) today announced that the Patent Trial and Appeal Board (PTAB) of the U.S. Patent and Trademark Office has issued written decisions on two Medtronic patents that Axonics is contesting. The PTAB issued its decision with respect to Patent Nos. 8,626,314 (“the ‘314 patent”) and 8,036,756 (“the ‘756 patent”). Medtronic has asserted these patents, which expired in 2021 and 2022, against Axonics' proprietary tined lead design. Today, the PT.
- 03/21/2024
|
Axonics (AXNX) Gets CE Mark for Sacral Neuromodulation System
- Axonics' (AXNX) fourth-generation rechargeable Sacral Neuromodulation system will reduce the frequency of patient recharges significantly. The new form factor ensures ease of use.
- 03/15/2024
|
Axonics Receives CE Mark Approval for Fourth-Generation Rechargeable Sacral Neuromodulation System
- IRVINE, Calif.--(BUSINESS WIRE)--Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, today announced that the Axonics R20™ rechargeable sacral neuromodulation (SNM) system has received CE Mark approval. The R20 neurostimulator is labeled for a functional life in the body of at least 20 years and reduces how frequently a patient needs to recharge their implanted device to once.
- 03/14/2024
|
Axonics Responds to ITC Action by Medtronic
- IRVINE, Calif.--(BUSINESS WIRE)--Axonics, Inc. (Nasdaq: AXNX) today announced that it has received notice that Medtronic has filed a complaint with the U.S. International Trade Commission (ITC), along with a parallel action in U.S. District Court for the District of Delaware. The complaint alleges that Axonics infringes two Medtronic patents that purportedly relate to a “patient programmer with automated MRI compatibility verification” for an implantable medical device. “We believe Medtronic's.
- 02/29/2024
|
Axonics Modulation Technologies (AXNX) Q4 Earnings and Revenues Surpass Estimates
- Axonics Modulation Technologies (AXNX) came out with quarterly earnings of $0.13 per share, beating the Zacks Consensus Estimate of $0.06 per share. This compares to earnings of $0.01 per share a year ago.
- 02/28/2024
|
AXONICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Axonics, Inc. - AXNX
- NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Axonics, Inc. (NasdaqGS: AXNX) to Boston Scientific Corporation (NYSE: BSX). Under the terms of the proposed transaction, shareholders of Axonics will receive $71.00 in cash for each share of Axonics that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequa.
- 02/27/2024
|
4 Stocks Backed by High Efficiency to Enrich Your Portfolio
- Invest in companies like Axonics (AXNX), Enerpac Tool Group (EPAC), Cardinal Health (CAH) and Acuity Brands (AYI) due to higher efficiency levels.
- 01/31/2024
|
Boston Scientific Announces Results for Fourth Quarter and Full Year 2023
- MARLBOROUGH, Mass. , Jan. 31, 2024 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) generated net sales of $3.725 billion during the fourth quarter of 2023, growing 14.9 percent on a reported basis, 14.5 percent on an operational1 basis and 13.6 percent on an organic2 basis, all compared to the prior year period.
- 01/31/2024
|
AXONICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Axonics, Inc. - AXNX
- NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Axonics, Inc. (NasdaqGS: AXNX) to Boston Scientific Corporation (NYSE: BSX). Under the terms of the proposed transaction, shareholders of Axonics will receive $71.00 in cash for each share of Axonics that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequa.
- 01/10/2024
|
Why Axonics Stock Soared Today
- Axonics has agreed to be acquired by Boston Scientific for $71 per share in cash. Assuming the deal receives the approval of shareholders and regulators, it should close in the first half of 2024.
- 01/08/2024
|
ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Axonics, Inc.
- NEW YORK , Jan. 8, 2024 /PRNewswire/ -- Rowley Law PLLC is investigating potential securities law violations by Axonics, Inc. (NASDAQ: AXNX) and its board of directors concerning the proposed acquisition of the company by Boston Scientific Corporation (NYSE: BSX). Stockholders will receive $71.00 for each share of Axonics stock that they hold.
- 01/08/2024
|
Why Is Axonics (AXNX) Stock Up 20% Today?
- Axonics (NASDAQ: AXNX ) stock is rising higher on Monday following news that Boston Scientific (NYSE: BSX ) is acquiring the company for $3.7 billion. That has Boston Scientific agreeing to purchase Axonics for $71 in cash per share.
- 01/08/2024
|
Axonix Stock Hits 52-Week High on Buyout Buzz
- The shares of Axonix Inc (NASDAQ:AXNX) are soaring today, after news that Boston Scientific (BSX) is acquiring the medical equipment name for approximately $3.7 billion, or $71 per share.
- 01/08/2024
|
Shareholder Alert: Ademi LLP investigates whether Axonics, Inc. has obtained a Fair Price in its transaction with Boston Scientific
- MILWAUKEE , Jan. 8, 2024 /PRNewswire/ -- Ademi LLP is investigating Axonics (Nasdaq: AXNX) for possible breaches of fiduciary duty and other violations of law in its transaction with Boston Scientific . Click here to learn how to join the https://www.ademilaw.com/case/axonics-inc or call Guri Ademi toll-free at 866-264-3995.
- 01/08/2024
|
AXNX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Axonics, Inc. Is Fair to Shareholders
- NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Axonics, Inc. (NASDAQ: AXNX) to Boston Scientific Corporation for $71.00 in cash per share is fair to Axonics shareholders. Halper Sadeh encourages Axonics shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or sadeh@halpersadeh.com or zhalper@halpersadeh.com. The investigation concerns whether Axonic.
- 01/08/2024
|
Axonics Stock Soars. It's Being Acquired By Boston Scientific In $3.7 Billion Deal.
- The move will expand Boston's product portfolio in its urology business.
- 01/08/2024
|
Boston Scientific to buy Axonics for $3.7 billion
- Boston Scientific said on Monday it had agreed to buy medtech company Axonics Inc for $3.7 billion.
- 01/08/2024
|
Axonics to Present at the J.P. Morgan Healthcare Conference
- IRVINE, Calif.--(BUSINESS WIRE)--Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, is scheduled to present at the J.P. Morgan Healthcare conference at 5:15 p.m. Pacific Time on Monday, January 8, 2024. Interested parties may access a live webcast and replay of the presentation by visiting the Axonics investor relations website. About Axonics Axonics is a global medical techn.
- 12/27/2023
|
Buy These 4 Low-Beta Stocks to Counter Market Volatility
- It is imperative to build a portfolio of low-beta stocks to sail through a volatile market. Virco Mfg (VIRC), Galapagos NV (GLPG), Axonics (AXNX) and Stride (LRN) are well-poised to gain.
- 12/15/2023
|
Goldman Sachs money manager digs into three themes for long-term growth
- Most exchange-traded funds are passively managed — they are designed to mirror the performance of stock indexes and typically have low management fees. They can work out very well for investors, which has been the case for funds that track the S&P 500.
- 12/05/2023
|
3 Stocks Backed by High Efficiency to Increase Portfolio Returns
- Invest in stocks of Axonics (AXNX), Bel Fuse (BELFB) and Thermon (THR) to tap their high-efficiency levels.
- 11/29/2023
|
Axonics to Participate in November Investor Conferences
- IRVINE, Calif.--(BUSINESS WIRE)--Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, is scheduled to participate in the following investor conferences in November: Event: Wolfe Research Healthcare Conference Date: Tuesday, November 14 Presentation time: 12:30 p.m. Eastern Time Event: Piper Sandler Healthcare Conference Date: Wednesday, November 29 Presentation time: 10:30 a.m.
- 11/01/2023
|
Axonics, Inc. (AXNX) Q3 2023 Earnings Call Transcript
- Axonics, Inc. (NASDAQ:AXNX ) Q3 2023 Earnings Conference Call October 30, 2023 4:30 PM ET Company Participants Neil Bhalodkar - Vice President of Investor Relations Raymond Cohen - Chief Executive Officer Kari Keese - Chief Financial Officer Conference Call Participants Chris Pasquale - Nephron Research Larry Biegelsen - Wells Fargo Travis Steed - Bank of America Securities Richard Newitter - Truist Securities Adam Maeder - Piper Sandler Mike Polark - Wolfe Research Mike Matson - Needham & Company David Rescott - Baird Kristen Stewart - CL King Shagun Singh - RBC Capital Markets Anthony Petrone - Mizuho Securities Kallum Titchmarsh - Morgan Stanley Michael Sarcone - Jefferies Mike Kratky - Leerink Partners Operator Ladies and gentlemen, thank you for standing by. Welcome to the Axonics Third Quarter 2023 Results Conference Call.
- 10/30/2023
|
Axonics Modulation Technologies (AXNX) Q3 Earnings and Revenues Top Estimates
- Axonics Modulation Technologies (AXNX) came out with quarterly earnings of $0.08 per share, beating the Zacks Consensus Estimate of a loss of $0.05 per share. This compares to loss of $0.34 per share a year ago.
- 10/30/2023
|
5 Top Stocks Set to Beat Q3 Earnings Estimates on Monday
- We have narrowed our search to five stocks that are set to declare third-quarter earnings on Monday. These are: XPO, ON, WELL, ACGL, AXNX.
- 10/27/2023
|
Axonics to Report Third Quarter 2023 Financial Results on October 30
- IRVINE, Calif.--(BUSINESS WIRE)--Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, is scheduled to report third quarter 2023 financial results after the close of trading on Monday, October 30. Axonics will host a conference call at 4:30 p.m. Eastern Time to discuss financial results. To access the conference call by telephone, interested parties may register at the following.
- 10/02/2023
|
Why Shares of Axonics Rose Friday
- Axonics is a medical device company that focuses on bladder and bowel dysfunction therapies. The company also upgraded its annual revenue guidance.
- 07/28/2023
|
Axonics, Inc. (AXNX) Q2 2023 Earnings Call Transcript
- Axonics, Inc. (NASDAQ:AXNX ) Q2 2023 Earnings Conference Call July 27, 2023 4:30 PM ET Company Participants Neil Bhalodkar - Vice President of Investor Relations Raymond Cohen - Chief Executive Officer Dan Dearen - President & Chief Financial Officer Conference Call Participants Chris Pasquale - Nephron Research Michael Polark - Wolfe Research Shagun Singh - RBC Capital Markets Operator That today's conference is being recorded. I would now like to hand the conference over to your speaker today, Neil Bhalodkar.
- 07/27/2023
|
Axonics Modulation Technologies (AXNX) Reports Q2 Loss, Tops Revenue Estimates
- Axonics Modulation Technologies (AXNX) came out with a quarterly loss of $0.15 per share versus the Zacks Consensus Estimate of a loss of $0.12. This compares to loss of $0.47 per share a year ago.
- 07/27/2023
|
Axonics to Report Second Quarter 2023 Financial Results on July 27
- IRVINE, Calif.--(BUSINESS WIRE)--Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, will report second quarter 2023 financial results after the close of trading on Thursday, July 27. Axonics will host a conference call at 4:30 p.m. Eastern Time to discuss financial results. To access the conference call by telephone, interested parties may register at the following link: Axon.
- 06/29/2023
|
Axonics, Inc. (AXNX) Q1 2023 Earnings Call Transcript
- Axonics, Inc. (NASDAQ:AXNX ) Q1 2023 Earnings Conference Call May 1, 2023 4:30 PM ET Company Participants Neil Bhalodkar - VP of IR Raymond Cohen - CEO Dan Dearen - President and CFO Conference Call Participants Chris Pasquale - Nephron Research Richard Newitter - Truist Securities Nathan Treyback - Wells Fargo Adam Maeder - Piper Sandler Michael Polark - Wolfe Research Shagun Singh - RBC Capital Markets Mike Matson - Needham and Company Anthony Petrone - Mizuho Securities Michael Sarcone - Jefferies Operator Thank you for standing by and welcome to the Axonics' First Quarter 2023 Results Conference Call. At this time, all participants are in listen-only mode.
- 05/01/2023
|
Axonics Modulation Technologies (AXNX) Reports Q1 Loss, Tops Revenue Estimates
- Axonics Modulation Technologies (AXNX) came out with a quarterly loss of $0.19 per share versus the Zacks Consensus Estimate of a loss of $0.34. This compares to loss of $0.50 per share a year ago.
- 05/01/2023
|
Axonics to Report First Quarter 2023 Financial Results on May 1
- IRVINE, Calif.--(BUSINESS WIRE)--Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, is scheduled to report first quarter 2023 financial results after the close of trading on Monday, May 1. Axonics will host a conference call at 4:30 p.m. Eastern Time to discuss financial results.
- 04/10/2023
|
Axonics, Inc. (AXNX) Q4 2022 Earnings Call Transcript
- Axonics, Inc. (NASDAQ:AXNX ) Q4 2022 Earnings Conference Call March 1, 2023 4:30 PM ET Company Participants Neil Bhalodkar - VP of IR Raymond Cohen - CEO Dan Dearen - President and CFO Conference Call Participants Travis Steed - Bank of America Larry Biegelsen - Wells Fargo Chris Pasquale - Nephron Research Cecilia Furlong - Morgan Stanley David Rescott - Truist Adam Maeder - Piper Sandler Michael Polark - Wolfe Research Shagun Singh - RBC Capital Markets Michael Sarcone - Jefferies Mike Matson - Needham and Company Operator Good day and thank you for standing by. Welcome to Axonics' Fourth Quarter 2022 Results Conference Call.
- 03/01/2023
|
Axonics Modulation Technologies (AXNX) Surpasses Q4 Earnings and Revenue Estimates
- Axonics (AXNX) delivered earnings and revenue surprises of 104.35% and 0.14%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
- 03/01/2023
|
Why Axonics (AXNX) Might Surprise This Earnings Season
- Axonics (AXNX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
- 02/28/2023
|
Axonics to Report Fourth Quarter 2022 Financial Results on March 1
- IRVINE, Calif.--(BUSINESS WIRE)--Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, will report fourth quarter 2022 financial results after the close of trading on Wednesday, March 1. Axonics will host a conference call at 4:30 p.m. Eastern Time to discuss financial results.
- 02/08/2023
|
6 Favorite Biotech Bets For 2023
- Biotechnology has often been among the most popular sectors in the MoneyShow Top Picks report, our annual survey of the nation's leading newsletter advisors. This year's report is no exception; here's a six-pack of favorite biotech ideas for the coming year.
- 01/09/2023
|
3 Hot Stocks Going Into the Holiday Weekend
- All three of these top-ranked stocks have recently gone on nice runs, giving shareholders some holiday cheer. Can the strength spill over into the new year?
- 12/23/2022
|
Axonics to Present at the 41st Annual J.P. Morgan Healthcare Conference
- IRVINE, Calif.--( BUSINESS WIRE )--Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, will present at the 41st Annual J.P. Morgan Healthcare Conference in San Francisco, California.
- 12/21/2022
|
Is Axonics (AXNX) Outperforming Other Medical Stocks This Year?
- Here is how Axonics Modulation Technologies (AXNX) and GlycoMimetics (GLYC) have performed compared to their sector so far this year.
- 12/19/2022
|
2 Fast-Growing Healthcare Stocks to Buy and Hold
- The innovative companies have made great gains in a short period of time.
- 12/02/2022
|
Axonics: Reaffirm Buy Following Q3 Strengths, Guidance Upgrade
- Following its Q3 FY23 financial results, AXNX management raised FY22 revenue guidance to $262mm, calling for 45% growth. Sacral neuromodulation revenue booked a record $59.6mm for the 3rd FY22 quarter, indicating strong market uptake.
- 11/24/2022
|
Are Medical Stocks Lagging Axonics (AXNX) This Year?
- Here is how Axonics Modulation Technologies (AXNX) and GlycoMimetics (GLYC) have performed compared to their sector so far this year.
- 11/16/2022
|
Axonics, Inc. (AXNX) Q3 2022 Earnings Call Transcript
- Axonics, Inc. (NASDAQ:AXNX ) Q3 2022 Earnings Conference Call October 31, 2022 4:30 PM ET Company Participants Neil Bhalodkar - Vice President of Investor Relations Raymond Cohen - Chief Executive Officer Dan Dearen - President & Chief Financial Officer Conference Call Participants Adam Maeder - Piper Sandler Chris Pasquale - Nephron Research Travis Steed - Bank of America Securities David Rescott - Truist Cecilia Furlong - Morgan Stanley Michael Polark - Wolfe Research Mike Matson - Needham & Company Operator Good day and thank you for standing by. Welcome to Axonics Q3 2022 Results Conference Call.
- 11/01/2022
|
Axonics Modulation Technologies (AXNX) Reports Q3 Loss, Tops Revenue Estimates
- Axonics (AXNX) delivered earnings and revenue surprises of 27.66% and 12.19%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
- 10/31/2022
|
Is a Surprise Coming for Axonics (AXNX) This Earnings Season?
- Axonics (AXNX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
- 10/27/2022
|
Is Axonics (AXNX) Outperforming Other Medical Stocks This Year?
- Here is how Axonics Modulation Technologies (AXNX) and Molina (MOH) have performed compared to their sector so far this year.
- 10/13/2022
|
Axonics® to Report Third Quarter 2022 Financial Results on October 31
- IRVINE, Calif.--(BUSINESS WIRE)--Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, will report third quarter 2022 financial results after the close of trading on Monday, October 31. Axonics will host a conference call at 4:30 p.m. Eastern Time to discuss financial results. Interested parties that would like to join the conference call by telephone are required to register in
- 10/10/2022
|
Leading Medical Stocks, Including Sensus And Shockwave, Have Grown At Least 36% This Year
- Biotech isn't the only place investors in health care stocks can make money in 2022. Take a look at leading medical-equipment stocks.
- 10/05/2022
|
Has Axonics (AXNX) Outpaced Other Medical Stocks This Year?
- Here is how Axonics Modulation Technologies (AXNX) and Molina (MOH) have performed compared to their sector so far this year.
- 09/26/2022
|
Axonics: Medical Devices Play
- 100% technical buy signals. 7 new highs and up 5.40% in the last month.
- 09/15/2022
|
Medical Device Maker Announces New Patients, Shoots Past Buy Point
- Axonics is breaking out from a three-weeks-tight pattern after announcing it has begin treating patients in Canada. The post Medical Device Maker Announces New Patients, Shoots Past Buy Point appeared first on Investor's Business Daily.
- 09/08/2022
|
Axonics Stock Is A Buy Amid Current Capex Cycle
- Axonics looks well-positioned to continue its recent upside on the chart, with a number of idiosyncratic tailwinds yet to be recognized. The recent equity underwriting of $35mm is noted, although this is hardly a risk given intended use for capital initiatives.
- 09/07/2022
|
Medical Stock Shows Strength In A Weakening Market; Nears Buy Point
- Medical device stock Axonics is near the buy point of a new basing pattern, which presents the potential for price gains ahead. The post Medical Stock Shows Strength In A Weakening Market; Nears Buy Point appeared first on Investor's Business Daily.
- 09/01/2022
|
Are Medical Stocks Lagging Axonics (AXNX) This Year?
- Here is how Axonics Modulation Technologies (AXNX) and Assertio (ASRT) have performed compared to their sector so far this year.
- 08/22/2022
|
Axonics® to Participate in September Investor Conferences
- IRVINE, Calif.--(BUSINESS WIRE)--Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, today announced that senior management is scheduled to present at the following investor conferences: Event: Wells Fargo Healthcare Conference Date: Thursday, September 8, 2022 Time: 10:25 a.m. Eastern Time Event: Morgan Stanley Healthcare Conference Date: Monday, September 12, 2022 Time: 11:0
- 08/18/2022
|
Here's Why Axonics Modulation Technologies (AXNX) is a Great Momentum Stock to Buy
- Does Axonics Modulation Technologies (AXNX) have what it takes to be a top stock pick for momentum investors? Let's find out.
- 08/08/2022
|
Is Axonics (AXNX) Stock Outpacing Its Medical Peers This Year?
- Here is how Axonics Modulation Technologies (AXNX) and Dynavax Technologies (DVAX) have performed compared to their sector so far this year.
- 08/04/2022
|
Axonics, Inc. (AXNX) CEO Raymond Cohen on Q2 2022 Results - Earnings Call Transcript
- Axonics, Inc. (NASDAQ:AXNX ) Q2 2022 Earnings Conference Call August 1, 2022 4:30 PM ET Company Participants Neil Bhalodkar - Investor Relations Raymond Cohen - Chief Executive Officer Dan Dearen - President & Chief Financial Officer Conference Call Participants Travis Steed - Bank of America Securities Adam Maeder - Piper Sandler Cecilia Furlong - Morgan Stanley Lawrence Biegelsen - Wells Fargo Securities Mike Polark - Wolfe Research Mike Matson - Needham & Company Operator Good day and thank you for standing by. Welcome to the Axonics Q2 2022 Results Conference Call.
- 08/01/2022
|
Axonics Modulation Technologies (AXNX) Reports Q2 Loss, Tops Revenue Estimates
- Axonics (AXNX) delivered earnings and revenue surprises of 17.54% and 16.48%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
- 08/01/2022
|
Is Axonics (AXNX) Outperforming Other Medical Stocks This Year?
- Here is how Axonics Modulation Technologies (AXNX) and DBV Technologies S.A. (DBVT) have performed compared to their sector so far this year.
- 07/19/2022
|
Axonics® to Report Second Quarter 2022 Financial Results on August 1
- IRVINE, Calif.--(BUSINESS WIRE)--Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, will report second quarter 2022 financial results after the close of trading on Monday, August 1. Axonics will host a conference call at 4:30 p.m. Eastern Time to discuss financial results. Interested parties that would like to join the conference call by telephone are required to register in
- 07/11/2022
|
Has Axonics (AXNX) Outpaced Other Medical Stocks This Year?
- Here is how Axonics Modulation Technologies (AXNX) and Bellus Health (BLU) have performed compared to their sector so far this year.
- 06/24/2022
|
3 Medical Info System Stocks Braving Industry Headwinds
- Medical Info Systems stocks like Omnicell, Inc. (OMCL), Axonics, Inc. (AXNX) and Outset Medical, Inc. (OM) are expected to gain despite pandemic-led disruptions.
- 06/23/2022
|
Axonics: A Strong Medical Device Play With Significant Revenue Growth Opportunities
- Axonics is a high-growth medical device play with strong revenue growth drivers. The company's rechargeable SNM system generates the vast majority of its sales.
- 05/30/2022
|
Axonics, Inc. (AXNX) CEO Raymond Cohen on Q1 2022 Results - Earnings Call Transcript
- Axonics, Inc. (NASDAQ:AXNX ) Q1 2022 Earnings Conference Call May 5, 2022 4:30 PM ET Company Participants Neil Bhalodkar - Investor Relations Raymond Cohen - Chief Executive Officer Dan Dearen - President & Chief Financial Officer Conference Call Participants Adam Maeder - Piper Sandler Cecilia Furlong - Morgan Stanley Mike Matson - Needham & Company David Rescott - Truist Securities Michael Polark - Wolfe Research Priya Sachdeva - SVB Securities Operator Good day. Thank you for standing by.
- 05/08/2022
|
Axonics Modulation Technologies (AXNX) Reports Q1 Loss, Tops Revenue Estimates
- Axonics (AXNX) delivered earnings and revenue surprises of 27.54% and 7.69%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
- 05/05/2022
|
Axonics, Inc. (AXNX) CEO Raymond Cohen on Q4 2021 Results - Earnings Call Transcript
- Axonics, Inc. (AXNX) CEO Raymond Cohen on Q4 2021 Results - Earnings Call Transcript
- 02/24/2022
|
Axonics Modulation Technologies (AXNX) Reports Q4 Loss, Tops Revenue Estimates
- Axonics (AXNX) delivered earnings and revenue surprises of 5.56% and 6.70%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
- 02/24/2022
|
Axonics® to Report Fourth Quarter and Fiscal Year 2021 Financial Results on February 24
- IRVINE, Calif.--(BUSINESS WIRE)--Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, will report fourth quarter and fiscal year 2021 financial results after the market closes on Thursday, February 24, 2022. In conjunction with the release, Axonics will host a conference call at 4:30 p.m. Eastern Time. Interested parties may access the live conference call by dialing 866-687-57
- 02/03/2022
|
Axonics (AXNX) Soars 7.4%: Is Further Upside Left in the Stock?
- Axonics (AXNX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
- 01/07/2022
|
Axonics, Inc. (AXNX) CEO Raymond Cohen on Q3 2021 Results - Earnings Call Transcript
- Axonics, Inc. (AXNX) CEO Raymond Cohen on Q3 2021 Results - Earnings Call Transcript
- 11/07/2021
|
Axonics® Provides Additional Update on Inter Partes Review Proceedings
- IRVINE, Calif.--(BUSINESS WIRE)--Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, today announced that the Patent Trial and Appeal Board (PTAB) of the U.S. Patent and Trademark Office has issued final written decisions on three additional Medtronic patents that Axonics is contesting. In March 2020, Axonics filed petitions with the PTAB requesting inter partes review (IPR) t
- 09/22/2021
|
U.S. Patent and Trademark Office Rejects Axonics' Challenge to Medtronic Patents
- DUBLIN, Sept. 13, 2021 /PRNewswire/ -- Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced it has won three additional important victories in a dispute over its intellectual property (IP) for its sacral neuromodulation device family, the InterStim™ systems.
- 09/13/2021
|
Axonics® Announces Partial Decision on Inter Partes Review Proceedings
- IRVINE, Calif.--(BUSINESS WIRE)--Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, today announced that the Patent Trial and Appeal Board (PTAB) of the U.S. Patent and Trademark Office has issued final written decisions on three of the six Medtronic patents that Axonics is contesting. In March 2020, Axonics filed petitions with the PTAB requesting inter partes review (IPR) t
- 09/13/2021
|
Axonics: Buy at the High?
- Axonics' stock price just hit its 52-week high, but its momentum means it's unlikely to last.
- 09/02/2021
|
Axonics® to Participate in Upcoming Investor Conferences
- IRVINE, Calif.--(BUSINESS WIRE)--Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, today announced that senior management will present at the following virtual investor conferences: Event: Wells Fargo Healthcare Conference Date: Thursday, September 9, 2021 Time: 12:00 p.m. Eastern Time Event: Morgan Stanley Healthcare Conference Date: Monday, September 13, 2021 Time: 12:30 p
- 08/27/2021
|
Axonics, Inc.'s (AXNX) CEO Raymond Cohen on Q2 2021 Results - Earnings Call Transcript
- Axonics, Inc.'s (AXNX) CEO Raymond Cohen on Q2 2021 Results - Earnings Call Transcript
- 08/08/2021
|
Axonics® Reports Second Quarter 2021 Financial Results
- IRVINE, Calif.--(BUSINESS WIRE)--Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, today reported financial results for the second quarter ended June 30, 2021. “This quarter's record revenue result reflects the growing demand for our best-in-class incontinence solutions,” said Raymond W. Cohen, chief executive officer of Axonics. “Clinical outcomes and satisfaction with our
- 08/05/2021
|
Axonics® Announces Appointment of Dr. Esteban López to its Board of Directors
- IRVINE, Calif.--(BUSINESS WIRE)--Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, today announced the appointment of Esteban López, M.D., MBA, to its board of directors, effective immediately. “Axonics is fortunate to have someone of Dr. López's character and extensive experience join our board of directors,” said Raymond W. Cohen, CEO of Axonics. “Given his thought leaders
- 07/15/2021
|
Axonics® to Report Second Quarter 2021 Financial Results on August 5, 2021
- IRVINE, Calif.--(BUSINESS WIRE)--Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, will report second quarter 2021 financial results after the market closes on Thursday, August 5, 2021. In conjunction with the release, Axonics will host a conference call at 4:30 p.m. Eastern Time. Interested parties may access the live conference call by dialing 866-687-5771 (U.S.) or 409-21
- 07/08/2021
|
Axonics® Files PMA Supplement with the FDA for Non-Rechargeable Implantable Sacral Neurostimulator
- IRVINE, Calif.--(BUSINESS WIRE)--Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, has filed a premarket approval (PMA) supplement with the FDA for its newly developed, long-lived, non-rechargeable sacral neuromodulation (SNM) implantable neurostimulator (INS). Axonics has designed its new non-rechargeable SNM system to replicate key features of its currently marketed, FDA-a
- 06/24/2021
|
Axonics® Receives FDA Approval Further Expanding MRI Labeling
- IRVINE, Calif.--(BUSINESS WIRE)--Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, has received FDA approval allowing the use of detachable extremity coils for patients undergoing 1.5T and 3.0T MRI scans. The FDA previously approved 1.5T and 3.0T MRI conditional labeling for using head and full-body transmit coils for the implantable components of the Axonics r-SNM® system.
- 05/20/2021
|
Axonics® Announces Closing of Public Stock Offering and Full Exercise of Underwriters' Option to Purchase Additional Stock
- IRVINE, Calif.--(BUSINESS WIRE)--Axonics, Inc. (Nasdaq: AXNX), (“Axonics”), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, today announced the closing of its public offering of 4,025,000 shares of common stock at the public offering price of $50.00 per share, which includes the exercise in full by the underwriters of the underwriters' option to purchase 525,000 additional shares at the public offering
- 05/14/2021
|
Axonics® Announces Upsize and Pricing of Public Offering of Common Stock
- IRVINE, Calif.--(BUSINESS WIRE)--Axonics, Inc. (Nasdaq: AXNX) (“Axonics”), a global medical technology company that has developed and is commercializing novel products for the treatment of bladder and bowel dysfunction, today announced the pricing of its public offering of 3,500,000 shares of its common stock at a public offering price of $50.00 per share, before underwriting discounts and commissions. The gross proceeds from the offering to Axonics, before deducting underwriting discounts and
- 05/11/2021
|
Axonics® Announces Proposed Public Offering of Common Stock
- IRVINE, Calif.--(BUSINESS WIRE)--Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, today announced that it has commenced a proposed public offering of $150,000,000 in shares of its common stock. Axonics expects to grant the underwriters a 30-day option to purchase up to $22,500,000 in additional shares of its common stock at the public offering price, less the underwriting d
- 05/11/2021
|
Axonics' (AXNX) CEO Raymond Cohen on Q1 2021 Results - Earnings Call Transcript
- Axonics' (AXNX) CEO Raymond Cohen on Q1 2021 Results - Earnings Call Transcript
- 05/09/2021
|
Axonics® to Participate in the BofA Securities 2021 Virtual Healthcare Conference
- IRVINE, Calif.--(BUSINESS WIRE)--Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that has developed and is commercializing novel products for the treatment of bladder and bowel dysfunction, is scheduled to participate in the BofA Securities 2021 Virtual Healthcare Conference on Thursday, May 13, 2021. Axonics is scheduled to present at 12:30 p.m. Eastern Time. A live webcast and archived replay of the presentation will be accessible on the Axonics investor relations website. A
- 04/22/2021
|
Axonics® to Report First Quarter 2021 Financial Results on May 6, 2021
- IRVINE, Calif.--(BUSINESS WIRE)--Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that has developed and is commercializing novel products for the treatment of bladder and bowel dysfunction, will report first quarter 2021 financial results after the market closes on Thursday, May 6, 2021. In conjunction with the release, Axonics will host a conference call at 4:30 p.m. Eastern Time. Interested parties may access the live conference call by dialing 866-687-5771 (U.S.) or 409-217
- 04/15/2021
|
Axonics® to Participate in the Barclays Global Healthcare Conference
- IRVINE, Calif.--(BUSINESS WIRE)--Axonics Modulation Technologies, Inc. (Nasdaq: AXNX), a global medical technology company that has developed and is commercializing novel products for the treatment of bladder and bowel dysfunction, is scheduled to participate in the virtual Barclays Global Healthcare Conference on March 10, 2021. Axonics is scheduled to present at 10:55 a.m. Eastern Time. Interested parties may access the live and archived webcast of the presentation by visiting the Axonics inv
- 03/03/2021
|
Axonics® Announces Strategic Alliance for the Manufacture of New Non-Rechargeable Implantable Sacral Neuromodulation Device
- IRVINE, Calif.--(BUSINESS WIRE)--Axonics Modulation Technologies, Inc. (Nasdaq: AXNX), a global medical technology company that has developed and is commercializing novel products for the treatment of bladder and bowel dysfunction, today announced it has entered into a strategic alliance with Micro Systems Technologies (MST), a leading manufacturer of medical microelectronics. MST currently manufactures printed circuit board assemblies for the Axonics r-SNM System in Lake Oswego, Oregon. This s
- 03/02/2021
|
Axonics Modulation Technologies' (AXNX) CEO Raymond Cohen on Q4 2020 Results - Earnings Call Transcript
- Axonics Modulation Technologies' (AXNX) CEO Raymond Cohen on Q4 2020 Results - Earnings Call Transcript
- 02/27/2021
|
Axonics Acquires Urethral Bulking Agent For $200M
- Axonics Modulation Technologies Inc (NASDAQ: AXNX) has acquired UK-based Contura and its lead product Bulkamid, a urethral bulking agent used to treat female stress urinary incontinence. The transaction includes a total consideration of $200 million in cash and stock, along with a potential future milestone of $35 million.
- 02/26/2021
|
Axonics Modulation Tech Earnings Preview
- On Thursday, February 25, Axonics Modulation Tech (NASDAQ:AXNX) will release its latest earnings report. Benzinga's outlook for Axonics Modulation Tech is included in the following report.
- 02/24/2021
|
Axonics® to Report Fourth Quarter and Fiscal Year 2020 Financial Results on February 25, 2021
- IRVINE, Calif.--(BUSINESS WIRE)--Axonics Modulation Technologies, Inc. (Nasdaq: AXNX), a medical technology company that has developed and is commercializing novel implantable sacral neuromodulation (SNM) devices for the treatment of urinary and bowel dysfunction, will report fourth quarter and fiscal year 2020 financial results after the market closes on Thursday, February 25, 2021. In conjunction with the release, Axonics will host a conference call at 4:30 p.m. Eastern Time. Interested parti
- 02/22/2021
|
Axonics® to Participate in the Society for Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction 2021 Winter Meeting
- IRVINE, Calif.--(BUSINESS WIRE)--Axonics Modulation Technologies, Inc. (Nasdaq: AXNX), a medical technology company that has developed and is commercializing novel implantable sacral neuromodulation (SNM) devices for the treatment of urinary and bowel dysfunction, today announced it is participating as a platinum sponsor of the Society for Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction (SUFU) 2021 Winter Meeting, which is being held virtually from February 25-27. Axonics is
- 02/18/2021
|
Axonics® Receives FDA Approval for Third-Generation Implantable Neurostimulator
- IRVINE, Calif.--(BUSINESS WIRE)--Axonics Modulation Technologies, Inc. (Nasdaq: AXNX), a medical technology company that has developed and is commercializing novel implantable sacral neuromodulation (SNM) devices for the treatment of urinary and bowel dysfunction, has received PMA supplement approval from the U.S. Food & Drug Administration (FDA) for its third-generation implantable neurostimulator (INS). This marks the sixth FDA approval Axonics has received for a significant product innov
- 02/16/2021
|
Axonics® to Participate in the SVB Leerink Global Healthcare Conference
- IRVINE, Calif.--(BUSINESS WIRE)--Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), a medical technology company that has developed and is commercializing novel implantable sacral neuromodulation (SNM) devices for the treatment of urinary and bowel dysfunction, will participate in the virtual SVB Leerink Global Healthcare Conference on February 24, 2021. Axonics' management team is scheduled to present at 11:20 a.m. Eastern Time. Interested parties may access the live and archived webcast of
- 02/11/2021
|
Axonics® Reports Preliminary Fourth Quarter and Fiscal Year 2020 Revenue
- IRVINE, Calif.--(BUSINESS WIRE)--Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), a medical technology company that has developed and is commercializing novel implantable sacral neuromodulation (SNM) devices for the treatment of urinary and bowel dysfunction, today reported preliminary unaudited net revenue for the three months and fiscal year ended December 31, 2020. Preliminary unaudited net revenue is expected to be in the range of $34.7 to $34.9 million in the fourth quarter 2020, as c
- 01/25/2021
|
Axonics® to Participate in Piper Sandler Virtual Healthcare Conference
- IRVINE, Calif.--(BUSINESS WIRE)--Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), a medical technology company that has developed and is commercializing novel implantable sacral neuromodulation (SNM) devices for the treatment of urinary and bowel dysfunction, is scheduled to participate in the Piper Sandler Virtual Healthcare Conference on December 1-2, 2020. In advance of the virtual conference and investor meetings, a pre-recorded fireside chat with Raymond W. Cohen, CEO of Axonics, will
- 11/19/2020
|
Axonics Modulation Technologies, Inc. (AXNX) CEO Raymond Cohen on Q3 2020 Results - Earnings Call Transcript
- Axonics Modulation Technologies, Inc. (AXNX) CEO Raymond Cohen on Q3 2020 Results - Earnings Call Transcript
- 11/04/2020
|
Axonics Modulation Technologies, Inc. (AXNX) CEO Raymond Cohen On Q3 2020 Results - Quick Earnings Call Transcript
- Axonics Modulation Technologies, Inc. (AXNX) CEO Raymond Cohen On Q3 2020 Results - Quick Earnings Call Transcript
- 11/04/2020
|
Axonics® Submits PMA Supplement to FDA to Further Expand MRI Labeling
- IRVINE, Calif.--(BUSINESS WIRE)--Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), a medical technology company that has developed and is commercializing novel implantable sacral neuromodulation (SNM) devices for the treatment of urinary and bowel dysfunction, has submitted a premarket approval (PMA) supplement to the FDA for the purpose of gaining detachable extremity coil magnetic resonance imaging (MRI) conditional labeling for 1.5T and 3.0T MR scanners. The FDA previously approved 1.5T
- 10/29/2020
|
Axonics® to Report Third Quarter 2020 Results on November 4
- Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), a medical technology company that has developed and is commercializing novel implantable sacral
- 10/14/2020
|
Axonics® CEO Raymond W. Cohen Named Ernst & Young Entrepreneur of the Year® 2020 Award Winner for Orange County
- Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), a medical technology company that has developed and is commercializing novel implantable sacral
- 10/07/2020
|
Agência do INSS de Suzano reabre, inclusive, para perícias
- OAB do município estima que durante fechamento 9,6 mil pessoas aguardavam por perícia.
- 10/05/2020
|
Axonics® Announces Survey Results of Patients Treated with the Axonics r-SNM System That Were Previously Implanted with InterStim II
- Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), a medical technology company that has developed and is commercializing novel implantable sacral
- 10/05/2020
|
Usar verba de precatórios para financiar novo programa social é inconstitucional, diz OAB
- Parecer é assinado pela Comissão de Precatórios e pelo presidente da OAB Nacional, Felipe Santa Cruz. Governo também anunciou que quer usar recursos do Fundeb para custear Renda Cidadã.
- 09/29/2020
|
Axonics® Provides Update on Inter Partes Review Proceedings
- Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), a medical technology company that has developed and is commercializing novel implantable sacral
- 09/24/2020
|
Axonics® Receives Health Canada Approval of Next Generation Implantable Neurostimulator
- Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), a medical technology company that has developed and is commercializing novel implantable sacral
- 09/21/2020
|
Médicos cubanos que atuavam no combate à Covid-19 no PA dizem que foram obrigados a abrir mão de vínculo empregatício
- Caso foi repassado à OAB que informou que vai acionar a Justiça do Trabalho. Segundo as denúncias, OS que administra hospitais em Belém disse que ato era necessário para que os profissionais atuassem no país.
- 08/26/2020
|
Axonics Modulation Technologies (NASDAQ:AXNX) Is Using Debt Safely
- Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
- 08/10/2020
|
Axonics Modulation Technologies (NASDAQ:AXNX) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway
- David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
- 08/10/2020
|
Gerbang Tol Cikunir 4 JORR mulai dioperasikan Selasa
- Gerbang Tol (GT) Cikunir 4 ruas lingkar luar Jakarta (JORR) mulai dioperasikan pada Selasa (11/8) pukul 00.00 WIB untuk meningkatkan pelayanan kepada pengguna ...
- 08/09/2020
|
Analysts' Top Healthcare Picks: Principia Biopharma (PRNB), Axonics Modulation Technologies (AXNX) - Markets
- There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Principia Biopharma
- 08/07/2020
|
The Daily Biotech Pulse: Novavax Vaccine Deals, Trevena Awaits FDA Decision, 2 IPOs
- Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Aug. 6)
ADiTx Therapeutics Inc (NASDAQ: ADTX) (announced introduction of AditxtScore for COVID-19 to be used in detecting...
- 08/07/2020
|
Axonics® Reports Second Quarter 2020 Results
- Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), a medical technology company that has developed and is commercializing novel implantable sacral neuromodulation (SNM) devices for the treatment of urinary and bowel dysfunction, today reported financial results for the second quarter 2020 and provided an update on operational initiatives.
- 08/06/2020
|
Axonics® Reports Second Quarter 2020 Results
- Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), a medical technology company that has developed and is commercializing novel implantable sacral
- 08/06/2020
|
Astellas Pharma's (ALPMF) Management on Q1 2021 Results - Earnings Call Transcript
- Astellas Pharma Inc (OTCPK:ALPMF) Q1 2021 Earnings Conference Call August 04, 2020 3:00 AM ET Company Participants Naoki Okamura – Representative Director and Executive Vice President Mike Kitagawa – Senior Vice President of Development Project Management Yukio Matsui – Chief Commercial Officer Conference Call Participants Hidemaru Yamaguchi – Citigroup Kazuaki Hashiguchi – Daiwa Securities Fumiyoshi Sakai – Crédit Suisse Securities Seiji Wakao – Mitsubishi UFJ Morgan Stanley Securities Presentation Naoki Okamura Thank you very much.
- 08/04/2020
|
AirHelp/Nielsen: legisla
- A guerra entre a
- 08/04/2020
|
Medtronic : Expands Leadership in Treating Bladder and Bowel Control Conditions with Two New FDA-Approved Products | MarketScreener
|
Axonics Modulation Technologies (AXNX) Set to Announce Quarterly Earnings on Thursday
- Axonics Modulation Technologies (NASDAQ:AXNX) is set to announce its earnings results after the market closes on Thursday, August 6th. Analysts expect the company to announce earnings of ($0.62) per share for the quarter. Investors interested in listening to the company’s conference call can do so using this link. Axonics Modulation Technologies (NASDAQ:AXNX) last released its […]
- 08/04/2020
|
The Daily Biotech Pulse: Voyager, AbbVie End Collaboration, Thumbs Down For DBV's Peanut Allergy Patch, Tiziana Expedites COVID-19 Trial Plans
- Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Aug. 3)
ABIOMED, Inc. (NASDAQ: ABMD)
ALX Oncology Holdings Inc (NASDAQ: ALXO)
Annexon Inc (NASDAQ: ANNX)
Atossa...
- 08/04/2020
|
Wall Street Analysts Are Bullish on Top Healthcare Picks - Markets
- There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on OncoCyte (OCX
- 08/03/2020
|
The Week Ahead In Biotech: Novavax Coronavirus Vaccine Readout, FDA Decisions And More Earnings
- Biotech stocks came under pressure in the week ended July 31 amid mixed earnings from the sector and some adverse clinical readouts.
COVID-19 news flow continued to pour in,...
- 08/02/2020
|
Axonics Modulation Technologies (AXNX) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
- Axonics (AXNX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 07/30/2020
|
Semana do Aleitamento Materno e do Bebê terá atividades online em Jundiaí
- Atividades virtuais sobre 'Primeiríssima Infância' serão realizadas entre segunda (3) e sexta-feira (7).
- 07/30/2020
|
The Daily Biotech Pulse: Merck's Breakthrough Therapy Designation, Sonoma Surges On Sanitizer News, Sanofi-Glaxo And More
- Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs July 28)
Axonics Modulation Technologies Inc (NASDAQ: AXNX)
Capricor Therapeutics Inc (NASDAQ: CAPR)
Fulgent Genetics Inc...
- 07/29/2020
|
Axonics® Announces 2-Year Topline Clinical Results from ARTISAN-SNM Pivotal Study
- Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), a medical technology company that has developed and is commercializing novel implantable sacral neuromodulation (SNM) devices for the treatment of urinary and bowel dysfunction, today announced completion of 2-year follow-ups and topline clinical results from its ARTISAN-SNM pivotal study that was conducted to evaluate the safety and efficacy of the Axonics r-SNM System®.
- 07/27/2020
|
Desembargador suspende investiga
- O desembargador Paulo Espirito Santo, do Tribunal Regional Federal da 2
- 07/19/2020
|
Did Hedge Funds Make The Right Call On Axonics Modulation Technologies, Inc. (AXNX) ?
- How do you pick the next stock to invest in? One way would be to spend days of research browsing through thousands of publicly traded companies. However, an easier way is to look at the stocks that smart money investors are collectively bullish on. Hedge funds and other institutional investors usually invest large amounts of […]
- 07/17/2020
|
Harel Insurance Investments & Financial Services Ltd. Buys New Position in Axonics Modulation Technologies Inc (NASDAQ:AXNX)
- Harel Insurance Investments & Financial Services Ltd. bought a new stake in shares of Axonics Modulation Technologies Inc (NASDAQ:AXNX) in the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 2,000 shares of the company’s stock, valued at approximately $70,000. Several other […]
- 07/17/2020
|
Axonics® to Report Second Quarter 2020 Results on August 6
- Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), a medical technology company that has developed and is commercializing novel implantable sacral neuromodulation (SNM) devices for the treatment of urinary and bowel dysfunction, will report financial results for the second quarter of 2020 after the market closes on Thursday, August 6, 2020.
- 07/16/2020
|
Stock Traders Purchase High Volume of Axonics Modulation Technologies Call Options (NASDAQ:AXNX)
- Axonics Modulation Technologies Inc (NASDAQ:AXNX) was the recipient of some unusual options trading activity on Monday. Investors bought 5,054 call options on the stock. This represents an increase of 801% compared to the typical daily volume of 561 call options. Axonics Modulation Technologies stock opened at $37.71 on Tuesday. The company has a debt-to-equity ratio […]
- 07/14/2020
|
Axonics® Reports Preliminary Second Quarter 2020 Revenue
- Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), a medical technology company that has developed and is commercializing novel implantable sacral neuromodulation (SNM) devices for the treatment of urinary and bowel dysfunction, today reported preliminary unaudited second quarter 2020 revenue and provided an operational update.
- 07/13/2020
|
Axonics® Reports Preliminary Second Quarter 2020 Revenue
- Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), a medical technology company that has developed and is commercializing novel implantable sacral
- 07/13/2020
|
The Daily Biotech Pulse: Ziopharm Starts Blood Cancer Study, Allergan's Botox Gets Label Expansion, 3 IPOs
- Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs July 9)
Affimed NV (NASDAQ: AFMD)...
- 07/10/2020
|
Geode Capital Management LLC Grows Stock Holdings in Axonics Modulation Technologies Inc (NASDAQ:AXNX)
- Geode Capital Management LLC lifted its position in shares of Axonics Modulation Technologies Inc (NASDAQ:AXNX) by 19.4% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 251,123 shares of the company’s stock after purchasing an additional 40,877 shares during the period. […]
- 07/06/2020
|
JPMorgan Chase & Co. Has $161,000 Stock Holdings in Axonics Modulation Technologies Inc (NASDAQ:AXNX)
- JPMorgan Chase & Co. increased its position in Axonics Modulation Technologies Inc (NASDAQ:AXNX) by 24.2% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 6,325 shares of the company’s stock after buying an additional 1,231 shares during the period. JPMorgan […]
- 07/05/2020
|
Squarepoint Ops LLC Sells 13,797 Shares of Axonics Modulation Technologies Inc (NASDAQ:AXNX)
- Squarepoint Ops LLC cut its holdings in shares of Axonics Modulation Technologies Inc (NASDAQ:AXNX) by 44.7% during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 17,051 shares of the company’s stock after selling 13,797 shares during the period. Squarepoint Ops LLC’s […]
- 07/03/2020
|
Hologic (HOLX) Gets a Buy Rating from Needham - Markets
- Needham analyst Michael Matson assigned a Buy rating to Hologic (HOLX – Research Report) today and set a price target
- 07/01/2020
|
Axonics® Receives FDA Approval for 3T Full-Body MRI Scans
- Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), a medical technology company that has developed and is commercializing novel implantable sacral neuromodulation (SNM) devices for the treatment of urinary and bowel dysfunction, today announced that it has received U.S. Food & Drug Administration (FDA) approval under a premarket approval supplement for 3T full-body magnetic resonance imaging (MRI) conditional labeling for the Axonics r-SNM System®.
- 07/01/2020
|
TJ afasta juiz do Maranhão denunciado em golpe de heranças milionárias
- Caso foi mostrado no Fantástico e cita o Juiz Márcio José do Carmo e o advogado Gustavo Santos Simeão.
- 07/01/2020
|
Combate à Covid-19: Prefeitura detalha pontos que terão trânsito interrompido no Centro de Salvador; confira
- Serão instaladas barreiras nos acessos às avenidas Sete de Setembro e Joana Angélica, assim como no bairro Dois de Julho.
- 07/01/2020
|
Axonics® Receives FDA Approval for 3T Full-Body MRI Scans
- Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), a medical technology company that has developed and is commercializing novel implantable sacral
- 07/01/2020
|
Idoso em situa
- O trabalhador e a m
- 06/30/2020
|
OAB vai investigar suposta participação de PMs em atentado à casa de presidente municipal do PT em Nuporanga, SP
- Entidade vai analisar imagens registradas por uma câmera de segurança durante o ataque com explosivos. Polícia Civil diz que discussão em rede social pode ter motivado a ação.
- 06/30/2020
|
Coronavírus: ocupação em UTIs da rede pública do DF chegou a 100% nesta madrugada
- Dados da regulação de leitos, obtidos pela TV Globo, apontavam 15 pessoas à espera de vaga. Secretaria de Saúde afirma que apenas índices oficiais 'refletem realidade'.
- 06/30/2020
|
Operação contra juízes, advogados e empresários em Goiás apura venda de decisões judiciais, diz MPF
- Em um dos casos, desembargador teria recebido R$ 800 mil para proferir uma sentença. PF cumpre 17 mandados de busca e apreensão autorizados pelo STJ.
- 06/30/2020
|
Analysts Offer Insights on Healthcare Companies: Cryolife (NYSE: CRY) and Seattle Genetics (NASDAQ: SGEN) - Markets
- There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Cryolife (CRY
- 06/30/2020
|
MP vai à Justiça exigir transparência após dados internos do GDF apontarem maior ocupação de UTIs que números oficiais
- Informações publicadas pela Secretaria de Saúde em site indicavam que 62% dos leitos estavam ocupados na manhã desta segunda (29). No entanto, documentos da pasta traziam índice de 94%.
- 06/29/2020
|
Defesa da democracia, das instituições e reação às fake news mostram efeito contrário ao pretendido por extremistas
|
AXONICS MODULATION TECHNOLOGIES, INC. : Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits (form 8-K) | MarketScreener
|
Aras abre 'apura
- O procurador-geral da Rep
- 06/25/2020
|
ONG lança cartilha para orientar mulheres em casos de violência doméstica em Franca, SP
- Encarte é distribuído gratuitamente em locais públicos e na internet para ajudar vítimas. Crimes relacionados à violência doméstica cresceram na quarentena, segundo o Ministério Público.
- 06/24/2020
|
Babá é presa suspeita de ajudar a planejar morte de mulher que sumiu ao chegar em aeroporto para ficar com a filha da vítima
- Segundo polícia, ela agiu na parte logística do crime com interesse em se tornar mãe da criança, de 4 anos. Investigação apontou que Lílian de Oliveira teve corpo carbonizado em fornalha. Dois homens já foram presos.
- 06/24/2020
|
Danny L. Dearen Sells 30,000 Shares of Axonics Modulation Technologies Inc (NASDAQ:AXNX) Stock
- Axonics Modulation Technologies Inc (NASDAQ:AXNX) insider Danny L. Dearen sold 30,000 shares of the stock in a transaction dated Thursday, June 18th. The shares were sold at an average price of $39.26, for a total transaction of $1,177,800.00. Following the completion of the sale, the insider now owns 84,240 shares of the company’s stock, valued […]
- 06/24/2020
|
Cartórios de MT fazem atendimentos pela internet durante pandemia da Covid-19
- Cartórios também passaram a fazer o atendimento por videoconferência.
- 06/23/2020
|
What Made Needham Upgrade NuVasive's Stock? - Markets
- In a report released today, Michael Matson from Needham upgraded NuVasive (NUVA – Research Report) to Buy, with a price
- 06/23/2020
|
Fux devolve ao TRF-1 decisão sobre legalidade de busca em escritório de ex-advogado de Adélio Bispo
- Ministro entendeu que não é competência do STF analisar o caso. Adélio Bispo confessou ter dado facada em 2018 no então candidato Jair Bolsonaro. PF concluiu que ele agiu sozinho.
- 06/22/2020
|
Wassef investigava entorno de Flávio Bolsonaro: Queiroz e miliciano Adriano
- Fabrício Queiroz e Adriano Nóbrega eram amigos antigos e se conheceram na Polícia Militar do Rio. Leia trechos da entrevista com advogado Frederick Wassef.
- 06/22/2020
|
‘Sharp-weapon wounds, multiple fractures in Galwan dead’
- Tourism destroyed, locked-down Leh struggles with Covid and tensions on China border.
- 06/21/2020
|
Wassef, dono do imóvel em que foi preso Queiroz, nega tê-lo escondido
- O advogado Frederick Wassef não explicou o que o ex-assessor de Flávio Bolsonaro fazia na casa e contradisse versão do Palácio do Planalto de que ele não representaria o presidente Jair Bolsonaro.
- 06/21/2020
|
Sumitovant Biopharma Announces Urovant Sciences Collaboration with Sunovion Pharmaceuticals
|
Advogados denunciam Vale do Rio Doce por n
- A Advogada Dra
- 06/20/2020
|
Tribunal de Justiça volta a proibir protestos de grupos contrários na Avenida Paulista e estabelece rodízio semanal
- O juiz Randolfo Ferraz de Campos determinou que a proibição tenha validade por tempo indeterminado, além de estipular multa de R$ 200 mil para as entidades e de R$ 1 mil para as pessoas físicas que desrespeitarem a liminar.
- 06/19/2020
|
Advogada pede que OAB/MG se posicione em den
- Fato ocorrido em 12 de mar
- 06/19/2020
|
Ativista postou há 1 mês foto na frente da casa de Wassef dizendo que Queiroz esteve em Atibaia
- Ex-assessor de Flávio Bolsonaro, Fabrício Queiroz, foi preso na quinta (17) no interior de São Paulo. Polícia diz que celular apreendido em operação no Rio apontou localização de Queiroz.
- 06/19/2020
|
A
- O ex-assessor parlamentar Fabr
- 06/19/2020
|
Advogado de Fl
- Wassef manteve escondido em um s
- 06/19/2020
|
Urovant Sciences Ltd (UROV) CEO James Robinson on Q4 2019 Results - Earnings Call Transcript
- Urovant Sciences Ltd (NASDAQ:UROV) Q4 2019 Earnings Conference Call June 18, 2020, 16:30 ET Company Participants Ryan Kubota - Executive Director, IR James Robi
- 06/19/2020
|
Urovant Sciences Ltd (UROV) Q4 2019 Earnings Call Transcript | The Motley Fool
- UROV earnings call for the period ending March 31, 2020.
- 06/19/2020
|
Mulher de Queiroz 'manifestou desejo de se esconder' caso tivesse prisão decretada, segundo MP
- Trecho de conversa com Fabrício Queiroz, preso nesta quinta-feira (18), consta na decisão da Justiça do Rio que determinou a prisão do ex-assessor. Até as 22h30 de quinta-feira, Márcia Aguiar era considerada foragida da Justiça.
- 06/19/2020
|
Galwan clash: Brutal injury marks on bodies; some die of hypothermia, asphyxiation
- Army officials said some of them had brutal injury marks on faces and other body parts.
- 06/19/2020
|
Por determinação da Justiça do RJ, polícia de SP prende Queiroz, ex-assessor de Flávio Bolsonaro
- Fabrício Queiroz estava em Atibaia, em uma casa registrada em nome do escritório de advocacia de Frederick Wassef, advogado de Flávio Bolsonaro. Segundo o caseiro, há cerca de um ano.
- 06/18/2020
|
Advogado de Bolsonaro n
- Ex-assessor de Fl
- 06/18/2020
|
Para evitar vazamentos, policiais n
- Ex-assessor de Fl
- 06/18/2020
|
Promotor diz que Queiroz ficou surpreso com prisão e não sabe se 'ele estava se escondendo ou era escondido por alguém'
- José Claudio Baglio, do Ministério Público em Campinas, disse que a ação foi realizada sem a certeza de que Queiroz estaria no imóvel. Defesa diz que ele teme pela própria vida.
- 06/18/2020
|
Urovant Sciences : Reports Fiscal Year and Fourth Quarter 2019 Results | MarketScreener
|
Senador Contarato pede
- O senador Fabiano Contarato (Rede-ES) encaminhou, nesta quinta-feira, 18, um of
- 06/18/2020
|
OAB não encontrou indícios de que casa onde Fabrício Queiroz foi preso era escritório de advocacia
- Integrantes da OAB de Campinas acompanharam cumprimento da prisão de Fabrício Queiroz e não encontraram nenhum documento que relacionasse o imóvel a um escritório de advocacia, conforme placa no local. Advogado poderá ser investigado por falta de ética.
- 06/18/2020
|
Healthy Aging | WholeFoods Magazine
|
Urovant Sciences : Announces Collaboration with Sunovion Pharmaceuticals | MarketScreener
|
Advogada e servidor do Fórum de Paripueira são presos em operação do MP-AL
- Servidor é suspeito de favorecer processos da advogada na cidade.
- 06/18/2020
|
Homem agredido por guardas municipais em Itajaí registra B.O.; Polícia Civil, Defensoria e OAB acompanham o caso
- Um dos guardas envolvidos foi encontrado morto em casa. Vítima, um pintor de 27 anos, ainda está com as marcas da violência pelo corpo.
- 06/18/2020
|
Urovant Sciences Announces Collaboration with Sunovion Pharmaceuticals
- Urovant Sciences (Nasdaq: UROV) today announced it has entered into an exclusive three-year distribution agreement with Sunovion Pharmaceuticals Inc.
- 06/18/2020
|
Is Axonics Modulation Technologies, Inc. (AXNX) Going to Burn These Hedge Funds?
- Before we spend countless hours researching a company, we like to analyze what insiders, hedge funds and billionaire investors think of the stock first. This is a necessary first step in our investment process because our research has shown that the elite investors' consensus returns have been exceptional. In the following paragraphs, we find out […]
- 06/17/2020
|
Câmara Legislativa recebe denúncias de falta de EPIs e pacientes internados em corredores de hospitais do DF
- Secretaria de Saúde e Iges-DF negam acusações. Comissão de Direitos Humanos da CLDF recebeu, desde março, 80 queixas relacionadas à saúde.
- 06/17/2020
|
Polícia solta 3 suspeitos de apologia ao nazismo na Avenida Paulista; alegação é a de que usavam camisas de rock
- Delegado soltou estudantes detidos por PM em ato pró-democracia e contra presidente Jair Bolsonaro, no domingo (14), dizendo que usavam símbolo de banda. Ouvidoria vê 'crime de ódio'.
- 06/16/2020
|
Justiça arquiva inquérito que apurava participação de terceiros em atentado contra Jair Bolsonaro
- Decisão é do juiz da 3ª Vara Federal de Juiz de Fora, cidade onde ocorreu o crime em 2018. Atualmente, o autor da facada, Adélio Bispo, está preso em Campo Grande (MS).
- 06/16/2020
|
Las puertas de Casa Seat se abren para Barcelona
- La instalación aglutinará debates, exposiciones y propuestas de futuro para unir la nueva movilidad, el automóvil y la conectividad en la filosofía de la ciudad del futuro
- 06/16/2020
|
Após chamar policial de 'macaco' e 'negro nojento', homem com outras 10 anotações criminais vai para presídio no Rio
- Além do crime de injúria e embriaguez ao volante, Mauricio Jorge Barcellos Fernandes ainda responderá por resistência à prisão e desacato. Anotações anteriores são por embriaguez ao volante, ameaça e lesão corporal.
- 06/15/2020
|
Sem crit
- Da Academia Mineira de Letras – Jornalista Não foi meu candidato no primeiro turno
- 06/15/2020
|
Micron Medical Appoints Seasoned Urology Executive Matthew Kemp as Chief Commercial Officer
- Micron Medical, a privately-held medical device company engaged in the development, manufacture and pre-commercialization of innovative wireless, minimally
- 06/15/2020
|
Manifestantes fazem ato em defesa da democracia e contra Bolsonaro em SP
- Torcidas de futebol, entidades estudantis e grupos antirracistas convocaram protesto na Avenida Paulista. Alguns apoiadores do presidente Jair Bolsonaro também realizaram ato no Viaduto do Chá, no Centro.
- 06/14/2020
|
Ministro Ramos afirma que é 'ultrajante' falar em golpe militar, mas alerta: 'Não estica a corda'
- Deputados e senadores interpretaram declaração como ameaça. General da ativa e responsável pela articulação política, ministro disse à revista 'Veja' que Bolsonaro 'nunca pregou golpe'.
- 06/12/2020
|
Fux diz que Forças Armadas não são 'poder moderador' em eventual conflito entre poderes
- Ministro do Supremo Tribunal Federal fez afirmação em decisão liminar (provisória) ao analisar pedido do PDT, que questionou pontos de leis que tratam da atuação das Forças Armadas.
- 06/12/2020
|
Urovant Sciences : to Report Fiscal Year and Fourth Quarter 2019 Results | MarketScreener
|
Jasa Marga siapkan teknologi pembayaran nir henti lewat uji coba SLFF
- PT Jasa Marga (Persero) Tbk. mempersiapkan implementasi teknologi pembayaran Nir Henti dengan terus melakukan uji coba terbatas pembayaran tol Single Lane ...
- 06/11/2020
|
MP fecha acordo com grupos contrários para implementar rodízio de protestos na Avenida Paulista aos domingos
- O objetivo é evitar confronto entre os manifestantes e com a Polícia Militar.
- 06/10/2020
|
Para Toffoli, Bolsonaro
- Enquanto apoiadores do presidente Jair Bolsonaro pedem interven
- 06/09/2020
|
Caso Miguel: garoto que morreu ao cair do 9º andar é homenageado em Tamandaré; prefeito é ex-patrão da mãe dele
- Grupo fez manifestação neste domingo na cidade que fica no Litoral Sul de Pernambuco. O prefeito é Sérgio Hacker (PSB), marido de Sari Corte Real, que tomava conta da criança.
- 06/07/2020
|
Manifestantes fazem ato contra Bolsonaro, contra o racismo e a favor da democracia em São Paulo
- Manifestação pacífica aconteceu na região do Largo da Batata; cerca de duas horas após o fim do ato, um pequeno grupo entrou em confronto com a PM, que usou bombas de efeito moral para dispersão. Na Avenida Paulista, grupo se manifestou a favor de Bolsonaro em frente ao prédio da Fiesp.
- 06/07/2020
|
Urovant Sciences: Still A Hidden Gem With Multiple Catalysts Approaching (NASDAQ:UROV)
- Urovant Sciences' Vibegron will likely win approved in December, providing a tailwind for the share price in the months leading to approval. Mirabegron, a compe
- 06/06/2020
|
Em carta, patroa pede perd
|
|
|
Coronav
- Grupo de Amigos e Familiares de Pessoas Privadas de Liberdade denunciam transfer
- 06/04/2020
|
Why Axonics Modulation's Stock Is Trading Higher Today
- Axonics Modulation Technologies Inc (NASDAQ: AXNX) shares are trading higher on Wednesday.The company reported FDA approval of its wireless patient remote control with MartMRI technology.Axonics Modulation Technologies Inc is a U.S. based medical technology company. It focuses on the design, development, and commercialization of innovative and minimally invasive sacral neuromodulation (SNM) solutions. SNM therapy is primarily used to treat patients with overactive bladder, fecal incontinence, and urinary retention.The company has designed and developed the r-SNM System, which delivers mild electrical pulses to the targeted sacral nerve in order to restore normal communication to and from the brain to reduce the symptoms of overactive bladder and fecal incontinenceAxonics Modulation shares were trading up 3.19% at $38.80 on Wednesday. The stock has a 52-week range between $43.37 and $15.25.See more from Benzinga * Why Frontline's Stock Is Trading Lower Today * Why Cracker Barrel's Stock Is Trading Higher Today * Why BPs' Stock Is Trading Higher Today(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
- 06/03/2020
|
Axonics® Announces U.S. Food & Drug Administration Approval of Wireless Patient Remote Control with SmartMRI Technology
- Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), a medical technology company that has developed and is commercializing novel implantable Sacral Neuromodulation (SNM) devices for the treatment of urinary and bowel dysfunction, today announced U.S. Food & Drug Administration (FDA) approval of its new wireless patient Remote Control with SmartMRI™ technology for the Axonics r-SNM® System under a premarket approval (PMA) supplement.
- 06/03/2020
|
Terça-feira, 2 de junho
- Boa noite! Aqui estão as notícias para você terminar o dia bem-informado.
- 06/02/2020
|
Alinhado a Bolsonaro, Aras diz que For
- O procurador-geral da Rep
- 06/02/2020
|
Movimentos pr
- Movimentos da sociedade civil com o objetivo de defender os valores democr
- 06/02/2020
|
Em plena pandemia, pol
- Em uma das ocorr
- 05/25/2020
|
Deputados pedem impeachment de general Augusto Heleno
- Ministro de Bolsonaro fez amea
- 05/25/2020
|
Barroso toma posse nesta segunda-feira como presidente do TSE
|
Nas quase 2h de reuni
- Encontro entre presidente e sua equipe ocorreu no dia 22 de abril, quando havia 2.906 mortes por covid-19 no Brasil; reuni
- 05/23/2020
|
Presidente da OAB 'recha
- Felipe Santa Cruz rebateu texto do ministro do Gabinete de Seguran
- 05/22/2020
|
Urovant Has Upside Potential Heading Into Vibegron's PDUFA Later This Year (NASDAQ:UROV)
- Urovant's lead product, Vibegron for OAD, has a PDUFA date in December 2020. Urovant has the backing of the large pharma company Sumitomo, including a much need
- 05/20/2020
|
Em reunião, Bolsonaro reclama de pressão para mostrar exames de Covid-19 e que impeachment por isso seria 'babaquice'
- Bolsonaro fez testes depois da confirmação de que membros de sua equipe haviam contraído a doença. STF obrigou a divulgação pública dos testes, que indicaram que o presidente teve resultado negativo para o novo coronavírus.
- 05/19/2020
|
Axonics® ARTISAN Results Published Demonstrating Continued Therapy Response and Patient Satisfaction at 1-year
- Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), a medical technology company focused on the development and commercialization of novel implantable Sacral Neuromodulation ("SNM") devices for the treatment of urinary and bowel dysfunction, today announced the publication of the 1-year results from its ARTISAN-SNM study in the peer-reviewed journal Neurourology & Urodynamics ("NAU") https://doi.org/10.1002/nau.24376. Axonics also plans to launch a multi-center registry study in the United States to collect additional real-world clinical evidence on the performance, safety and patient experience with the Axonics r-SNM® System across all approved indications to advance physician knowledge and patient access to rechargeable sacral neuromodulation therapy.
- 05/19/2020
|
Axonics Modulation's Shares March Higher, Can It Continue?
- As of late, it has definitely been a great time to be an investor in Axonics Modulation Technologies.
- 05/19/2020
|
Axonics® ARTISAN Results Published Demonstrating Continued Therapy Response and Patient Satisfaction at 1-year
- Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), a medical technology company focused on the development and commercialization of novel implantab
- 05/19/2020
|
Políticos, entidades médicas e sociedade civil reagem à saída de mais um ministro da Saúde
- Nova mudança provoca preocupação da comunidade médica e científica no Brasil e no exterior, e críticas contundentes de governadores que enfrentam a escalada de mortes nos estados.
- 05/15/2020
|
|
|
Grupo protesta em frente casa de juíza que revogou decreto em Itajubá, MG
- Judiciário mandou revogar na terça-feira decreto da prefeitura que permitia reabertura de bares, restaurantes, igrejas e academias.
- 05/14/2020
|
Coronavírus: MP que isenta agente público de punição é 'obscura', diz Gilson Dipp
- Texto livra de punição eventuais 'omissões' de agentes públicos. Ministro aposentado do STJ afirmou que MP protege essencialmente pessoas do Executivo, inclusive da Presidência.
- 05/14/2020
|
PF conclui em 2º inquérito que Adélio agiu sozinho e sem mandantes no ataque a Bolsonaro
- Investigações apontam que não foi comprovada, por exemplo, a participação no crime de agremiações partidárias, facções criminosas, grupos terroristas ou paramilitares.
- 05/14/2020
|
Urovant Sciences Presents Positive Clinical Efficacy & Safety Data on Lead Drug Candidate Vibegron at Virtual American Urological Association Annual Meeting
- Urovant Sciences (Nasdaq: UROV) announced today that data from the vibegron EMPOWUR 52-week extension study (NCT03583372) and data by age groups from
- 05/14/2020
|
Poá abre processo de licitação para a demolição do prédio do antigo fórum do município
- Prefeitura havia conseguido autorização para demolir o imóvel no último mês. Local está desativado desde 2009 e fórum funciona em edifício que foi adaptado para o serviço.
- 05/13/2020
|
Aiming to thwart China, U.S. senator pushes rare earths funding bill
- U.S. Senator Ted Cruz introduced legislation on Tuesday to help revive the U.S. rare earths industry with tax breaks for mine developers and manufacturers who buy their products, the latest attempt by Washington to break China's control over the strategic sector. China is the largest global processor of rare earths, a group of 17 minerals used to make electronics and military equipment. The country has threatened to stop exporting the specialized minerals to the United States amid the ongoing trade war, prompting efforts by Washington to help revive its domestic rare earths industry.
- 05/12/2020
|
Axonics® Announces Closing of Public Stock Offering and Full Exercise of Underwriters’ Option to Purchase Additional Stock
- Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), (“Axonics”), a medical technology company that has developed and is commercializing novel implantable...
- 05/12/2020
|
Axonics® Announces Closing of Public Stock Offering and Full Exercise of Underwriters’ Option to Purchase Additional Stock
- Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), ("Axonics"), a medical technology company that has developed and is commercializing novel implantable rechargeable sacral neuromodulation ("SNM") devices for the treatment of bladder and bowel dysfunction, today announced the closing of its public offering of 4,600,000 shares of common stock at the public offering price of $32.50 per share, which includes the shares purchased pursuant to the exercise in full of the underwriters’ option to purchase up to an additional 600,000 shares of its common stock. The gross proceeds from the offering to Axonics, before deducting underwriting discounts and commissions and estimated offering expenses, were approximately $149.5 million.
- 05/12/2020
|
Axonics® Announces Closing of Public Stock Offering and Full Exercise of Underwriters’ Option to Purchase Additional Stock
- Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), (“Axonics”), a medical technology company that has developed and is commercializing novel implan
- 05/12/2020
|
Penitenciária do Amapá registra 1º caso suspeito de Covid-19 entre detentos
- Caso está em investigação. Iapen também aponta que 14 servidores testaram positivo para o novo vírus; outros 30 têm sintomas e 42 foram afastados porque são do grupo de risco.
- 05/11/2020
|
Procon de São Carlos sugere diálogo sobre mensalidade de escolas durante a quarentena
- Como não há lei específica, intenção do órgão é promover diálogo entre instituição e consumidor para a revisão de contratos. Também sugere que colégios divulguem planilha de custos.
- 05/11/2020
|
Rodízio de carros na Grande São Luís começa nesta segunda-feira
- Região metropolitana está em regime de lockdown desde terça-feira (5). Rodízio deve durar quatro dias.
- 05/11/2020
|
Axonics Modulation Technologies, Inc. (AXNX) CEO Raymond Cohen on Q1 2020 Results - Earnings Call Transcript
- Axonics Modulation Technologies, Inc. (NASDAQ:AXNX) Q1 2020 Earnings Conference Call May 05, 2020 04:30 PM ET Company Participants Neil Bhalodkar - Investor Rel
- 05/09/2020
|
OAB pede que STF suspenda autorização para novos cursos de direito
- Entidade que representa advogados quer decisão liminar (provisória) para impedir que cursos sejam autorizados durante a pandemia. Além disso, OAB pede a mesma restrição por cinco anos.
- 05/08/2020
|
STF mantém suspensa a MP que determinava compartilhamento de dados com o IBGE
- A relatora, ministra Rosa Weber, argumentou que a suspensão da medida provisória previne danos irreparáveis à intimidade e ao sigilo da vida privada de milhares de usuários.
- 05/08/2020
|
Axonics® Announces Pricing of Public Offering of Common Stock
- Axonics Modulation Technologies, Inc. (NASDAQ: AXNX) ("Axonics"), a medical technology company that has developed and is commercializing novel implantable rechargeable sacral neuromodulation ("SNM") devices for the treatment of bladder and bowel dysfunction, today announced the pricing of its public offering of 4,000,000 shares of its common stock at a public offering price of $32.50 per share, before underwriting discounts and commissions. The gross proceeds from the offering to Axonics, before deducting underwriting discounts and commissions and estimated offering expenses, are expected to be $130 million. In addition, the underwriters have a 30-day option to purchase up to an additional 600,000 shares of common stock from Axonics on the same terms and conditions. The offering is expected to close on May 12, 2020, subject to the satisfaction of customary closing conditions.
- 05/08/2020
|
Axonics® Announces Pricing of Public Offering of Common Stock
- Axonics Modulation Technologies, Inc. (NASDAQ: AXNX) (“Axonics”), a medical technology company that has developed and is commercializing novel implant
- 05/08/2020
|
Axonics® Announces Proposed Public Offering of Common Stock
- Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), a medical technology company that has developed and is commercializing novel implantable rechargeable sacral neuromodulation ("SNM") devices for the treatment of bladder and bowel dysfunction, today announced that it has commenced a proposed public offering of $100,000,000 in shares of its common stock. Axonics expects to grant the underwriters a 30-day option to purchase up to $15,000,000 in additional shares of its common stock at the public offering price, less the underwriting discount.
- 05/07/2020
|
The Axonics Modulation Technologies, Inc. (NASDAQ:AXNX) First-Quarter Results Are Out And Analysts Have Published New Forecasts
- As you might know, Axonics Modulation Technologies, Inc. (NASDAQ:AXNX) just kicked off its latest first-quarter...
- 05/07/2020
|
The Daily Biotech Pulse: FDA Nod For AstraZeneca, AbbVie-Allergan Deal Clears Antitrust Hurdle
- Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peak
(Biotech Stocks Hitting 52-week Highs May 5)
• Adverum Biotechnologies...
- 05/06/2020
|
Axonics Modulation Technologies (AXNX) Reports Q1 Loss, Tops Revenue Estimates
- Axonics (AXNX) delivered earnings and revenue surprises of 23.21% and 87.56%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
- 05/05/2020
|
Axonics® Reports First Quarter 2020 Results
- Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), a medical technology company that has developed and is commercializing novel implantable Sacral Neuromodulation ("SNM") devices for the treatment of urinary and bowel dysfunction, today reported financial results for the first quarter 2020 and provided an update on operational initiatives.
- 05/05/2020
|
Justiça Federal suspende trechos de portaria do Iapen que restringe visita de advogados em presídios do AC
- OAB entrou na Justiça por entender que portaria não deixava claro quais atendimentos eram considerados urgentes. Iapen restringiu visitas por conta da pandemia de Covid-19.
- 05/05/2020
|
Fux pede a PGR e OAB que opinem sobre proposta de levar a plenário decisão sobre ato de outro poder
- Proposta do ministro Marco Aurélio Mello deve ser discutida em sessão administrativa do Supremo Tribunal Federal.
- 05/05/2020
|
The Daily Biotech Pulse: Bio-Rad's Coronavirus Test Gets EUA, Beat-And-Raise Quarter From GenMark, Adverum's Positive Gene Therapy Readout
- Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech stocks hitting 52-week highs May 5.)
Arcturus Therapeutics Ltd (...
- 05/05/2020
|
Axonics® to Present at Upcoming Investor Conferences
- Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), a medical technology company that has developed and is commercializing novel implantable Sacral Neuromodulation ("SNM") devices for the treatment of urinary and bowel dysfunction, announced today that members of the senior management team will present at the following upcoming investor conferences and will be available for meetings with institutional investors:
- 05/04/2020
|
Axonics® to Present at Upcoming Investor Conferences
- Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), a medical technology company that has developed and is commercializing novel implantable Sacral
- 05/04/2020
|
Maia diz que 'cabe às instituições democráticas impor ordem legal ao grupo que confunde política com terror'
- Presidente da Câmara criticou ato com pauta antidemocrática e inconstitucional em Brasília com participação de Bolsonaro. 'Lutamos contra o coronavírus e o vírus do extremismo', diz Maia.
- 05/03/2020
|
Juristas, políticos e entidades reagem a nova participação de Bolsonaro em ato antidemocracia
- Presidente cumprimentou apoiadores aglomerados em ato pró-intervenção militar e contra Congresso e STF. Ele disse que 'chegamos no limite' e que 'não vai admitir mais interferência'.
- 05/03/2020
|
The Week Ahead In Biotech: Smid-Cap Earnings News Flow Picks Up Pace
- Biotech stocks started last week on a strong note but the upward momentum slowed through the week. The week saw a slew of earnings from big pharma names, including Merck...
- 05/03/2020
|
Axonics Modulation Technologies (NASDAQ:AXNX) Lowered to "Buy" at BidaskClub
- BidaskClub lowered shares of Axonics Modulation Technologies (NASDAQ:AXNX) from a strong-buy rating to a buy rating in a research note released on Friday, BidAskClub reports. Several other equities research analysts have also recently commented on AXNX. Wells Fargo & Co dropped their price target on shares of Axonics Modulation Technologies from $47.00 to $35.00 and […]
- 05/02/2020
|
Axonics Modulation Technologies Target of Unusually High Options Trading (NASDAQ:AXNX)
- Axonics Modulation Technologies Inc (NASDAQ:AXNX) was the target of unusually large options trading activity on Thursday. Stock traders purchased 628 call options on the stock. This is an increase of 1,063% compared to the typical daily volume of 54 call options. In other Axonics Modulation Technologies news, CEO Raymond W. Cohen sold 10,000 shares of […]
- 05/02/2020
|
Ato virtual de 1º de Maio exibe em redes sociais mensagens gravadas de políticos e ex-presidentes
- Evento promovido por centrais sindicais para celebrar o Dia do Trabalhador durou mais de seis horas e também contou com apresentações de artistas, como Roger Waters e Zélia Duncan.
- 05/01/2020
|
Após Bolsonaro criticar decisão de Alexandre de Moraes, colegas do STF fazem elogios ao ministro
- Presidente classificou de 'política' decisão liminar (provisória) do ministro, que apontou 'desvio de finalidade' e suspendeu nomeação do delegado Alexandre Ramagem para a direção da PF.
- 04/30/2020
|
STF derruba restrições à Lei de Acesso à Informação previstas em MP editada por Bolsonaro
- Presidente editou medida em março, e Rede Sustentabilidade pediu ao STF que suspendesse trechos que restringiam a LAI. Relator atendeu a pedido, e o plenário confirmou a decisão.
- 04/30/2020
|
BRIEF-Axonics Names Michael Carrel As Chairman Of Its Board Of Directors
- Axonics Modulation Technologies Inc :
- 04/29/2020
|
Axonics® Names Michael H. Carrel as Chairman of its Board of Directors
- Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), a medical technology company that has developed and is commercializing novel implantable Sacral Neuromodulation ("SNM") devices for the treatment of urinary and bowel dysfunction, announced today the appointment of Michael H. Carrel as chairman of the Axonics board of directors. Concurrent with this appointment, Raphael Wisniewski, who has served as chairman of Axonics since the Company’s inception in late 2013, is retiring and will not stand for re-election at the 2020 annual meeting of stockholders.
- 04/29/2020
|
Analysts Estimate Axonics Modulation Technologies (AXNX) to Report a Decline in Earnings: What to Look Out for
- Axonics (AXNX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 04/28/2020
|
Analysts Estimate Axonics Modulation Technologies (AXNX) to Report a Decline in Earnings: What to Look Out for
- Axonics (AXNX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 04/28/2020
|
Did Axonics Modulation Technologies’ (NASDAQ:AXNX) Share Price Deserve to Gain 73%?
- These days it's easy to simply buy an index fund, and your returns should (roughly) match the market. But investors...
- 04/28/2020
|
Axonics Modulation Technologies (AXNX) Scheduled to Post Quarterly Earnings on Tuesday
- Axonics Modulation Technologies (NASDAQ:AXNX) will announce its earnings results after the market closes on Tuesday, May 5th. Analysts expect the company to announce earnings of ($0.59) per share for the quarter. Investors that are interested in participating in the company’s conference call can do so using this link. Axonics Modulation Technologies (NASDAQ:AXNX) last released its […]
- 04/28/2020
|
Nuveen Asset Management LLC Has $3.41 Million Position in Axonics Modulation Technologies Inc (NASDAQ:AXNX)
- Nuveen Asset Management LLC lifted its position in shares of Axonics Modulation Technologies Inc (NASDAQ:AXNX) by 92.8% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 122,878 shares of the company’s stock after buying an additional 59,140 shares during the period. Nuveen […]
- 04/26/2020
|
Brasil camina a ciegas con Bolsonaro, amenazado de ‘impeachment’ después de la salida de Moro
- Electores del presidente se decepcionan, mientras crece la presión por su salida y el mercado financiero pierde el rumbo
- 04/25/2020
|
Geode Capital Management LLC Boosts Stake in Axonics Modulation Technologies Inc (NASDAQ:AXNX)
- Geode Capital Management LLC grew its stake in Axonics Modulation Technologies Inc (NASDAQ:AXNX) by 34.5% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 210,246 shares of the company’s stock after buying an additional 53,951 shares during the period. Geode […]
- 04/25/2020
|
Axonics Modulation Technologies (NASDAQ:AXNX) Price Target Cut to $44.00 by Analysts at Piper Sandler
- Axonics Modulation Technologies (NASDAQ:AXNX) had its price target cut by Piper Sandler from $48.00 to $44.00 in a research note released on Tuesday morning, The Fly reports. The firm currently has an overweight rating on the stock. Piper Sandler also issued estimates for Axonics Modulation Technologies’ Q1 2020 earnings at ($0.66) EPS, Q2 2020 earnings […]
- 04/25/2020
|
Brazil 'super minister' quits in Bolsonaro's worst crisis yet
- Brazil's Jair Bolsonaro suffered the heaviest blow to his presidency so far as his popular justice minister quit on Friday and accused him of potentially criminal meddling in law enforcement, adding to the turmoil of a government struggling to confront a fast-growing coronavirus outbreak.
- 04/25/2020
|
Q1 2020 EPS Estimates for Axonics Modulation Technologies Inc Lifted by Piper Sandler (NASDAQ:AXNX)
- Axonics Modulation Technologies Inc (NASDAQ:AXNX) – Equities research analysts at Piper Sandler lifted their Q1 2020 earnings per share estimates for Axonics Modulation Technologies in a research note issued to investors on Tuesday, April 21st. Piper Sandler analyst A. Maeder now forecasts that the company will post earnings of ($0.66) per share for the quarter, […]
- 04/24/2020
|
Bank of New York Mellon Corp Has $1.81 Million Stock Position in Axonics Modulation Technologies Inc (NASDAQ:AXNX)
- Bank of New York Mellon Corp reduced its stake in Axonics Modulation Technologies Inc (NASDAQ:AXNX) by 13.3% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 65,218 shares of the company’s stock after selling 10,022 shares during the quarter. Bank of […]
- 04/22/2020
|
Axonics Modulation Technologies (NASDAQ:AXNX) Rating Increased to Strong-Buy at BidaskClub
- Axonics Modulation Technologies (NASDAQ:AXNX) was upgraded by analysts at BidaskClub from a “buy” rating to a “strong-buy” rating in a research note issued to investors on Wednesday, BidAskClub reports. Other analysts have also recently issued research reports about the company. Needham & Company LLC reissued a “buy” rating and issued a $48.00 price objective on […]
- 04/22/2020
|
The Axonics Modulation Technologies (NASDAQ:AXNX) Share Price Has Gained 78% And Shareholders Are Hoping For More
- If you want to compound wealth in the stock market, you can do so by buying an index fund. But if you pick the right...
- 04/20/2020
|
Axonics Modulation Technologies Inc (NASDAQ:AXNX) Stock Position Raised by Alliancebernstein L.P.
- Alliancebernstein L.P. boosted its position in shares of Axonics Modulation Technologies Inc (NASDAQ:AXNX) by 18.4% during the 4th quarter, HoldingsChannel reports. The firm owned 22,500 shares of the company’s stock after buying an additional 3,500 shares during the quarter. Alliancebernstein L.P.’s holdings in Axonics Modulation Technologies were worth $623,000 at the end of the most […]
- 04/19/2020
|
BRIEF-Axonics Modulation Says Most Employees To Take Temporary 20% Cut In Base Salary For Remainder Of Q2 2020
- Axonics Modulation Technologies Inc :
- 04/16/2020
|
Analysts Are Bullish on These Healthcare Stocks: Moleculin Biotech (MBRX), Axonics Modulation Technologies (AXNX)
- There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Moleculin Biotech (
MBRX
–
Research Report
) and Axonics Modulation Technologies (
AXNX
–
Research Report
) with bullish sentiments.
Moleculin Biotech (MBR
- 04/15/2020
|
Axonics Modulation Technologies Inc (NASDAQ:AXNX) Shares Purchased by Bank of America Corp DE
- Bank of America Corp DE increased its holdings in shares of Axonics Modulation Technologies Inc (NASDAQ:AXNX) by 425.4% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 143,622 shares of the company’s stock after acquiring an additional 116,284 shares during the period. Bank of […]
- 04/15/2020
|
Axonics Modulation Technologies Inc (NASDAQ:AXNX) Given Consensus Recommendation of "Buy" by Brokerages
- Shares of Axonics Modulation Technologies Inc (NASDAQ:AXNX) have been assigned a consensus recommendation of “Buy” from the twelve brokerages that are covering the firm, Marketbeat Ratings reports. One analyst has rated the stock with a hold rating and eleven have given a buy rating to the company. The average 1-year price objective among analysts that […]
- 04/15/2020
|
BRIEF-Axonics Says U.S. FDA Approves Implantable Neurostimulator
- Axonics Modulation Technologies Inc :
- 04/14/2020
|
Axonics® Announces U.S. Food & Drug Administration Approval of Next Generation Implantable Neurostimulator
- Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), a medical technology company that has developed and is commercializing novel implantable sacral neuromodulation ("SNM") devices for the treatment of urinary and bowel dysfunction, today announced the U.S. Food & Drug Administration ("FDA") approval of its next generation rechargeable implantable neurostimulator ("INS") for its r-SNM® System under a premarket approval ("PMA") supplement.
- 04/14/2020
|
